NL-OMON40793RecruitingNot Applicable
Dose-to-target of etanercept treatment: a dose-tapering randomized controlled trial in patients with juvenile idiopathic arthritis in patients age 12 years and older. - Dose-to-target of etanercept in patients with JIA age >=12 years
Jan van Breemen Instituut0 sites40 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 40
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 12 to 99 (—)
Inclusion Criteria
- •Diagnosis: JIA, types: polyarthritis (RF negative and RF positive), oligo-arthritis (persistant and extended), psoriasic and enthesitis related arthritis and undifferentiated arthritis (according to the ILAR criteria).
- •Age 12 years or older.
- •Treatment with etanercept 50 mg SC weekly (or 25 mg SC twice weekly) or treatment with weekly dose etanercept of 0,8 mg/kg for at least 6 subsequent months.
- •Minimal Disease Activity, according to the JADAS criteria for Minimal Disease Activity at baseline and clinically low disease activity according to the rheumatologist for at least 6 months to baseline.
- •No uveitis for a minimum of 12 months.
- •No use of systemic corticosteroids or intra-articular steroids for a minimum of 6 months prior to baseline.
- •Written informed consent by the patient (and if applicable, the parents).
Exclusion Criteria
- •Planned reasons for treatment discontinuation.
- •JIA, type: systemic arthritis.
Investigators
Similar Trials
Recruiting
Not Applicable
Dose-to-target of etanercept treatment: a dose-tapering randomized controlled trial in patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis.rheumatoid arthritisankylosing spondylitispsoriatic arthritis10003816NL-OMON38584Jan van Breemen Instituut250
Not yet recruiting
Not Applicable
Dose-to-target of etanercept treatment in patients with juvenile idiopathic arthritis in patients age 12 years and older.etanercept, juvenile idiopathic arthritis, dose tapering, discontinuationNL-OMON20690Jan van Breemen Instituut, Reade40
Not yet recruiting
Not Applicable
Dose-to-target of etanercept treatment in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.Etanercept, dose-to-target, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, personalized medicineNL-OMON24861Jan van Breemen Research Institute | Reade250
Not yet recruiting
Phase 4
Prospective study on the effects of etanercept treatment in patients with rheumatoid arthritis who are naive for TNF-alpha blocking therapy or are non-responders to prior treatment with other anti-TNF-alpha medicatio1000381610023213rheumatoid arthritisNL-OMON32681Academisch Medisch Centrum200
Active, not recruiting
Not Applicable
Prospective study on the effects of etanercept treatment in patients with rheumatoid arthritis who are naïve for TNF-alpha blocking therapy and patients who do not respond (anymore) to prior treatment with other anti-TNF-alpha medication - Not applicablerheumatoid arthritisMedDRA version: 12.0Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2009-015653-20-NL